194 related articles for article (PubMed ID: 20305694)
1. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
[TBL] [Abstract][Full Text] [Related]
2. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.
Kannan N; Kang J; Kong X; Tang J; Perry JK; Mohankumar KM; Miller LD; Liu ET; Mertani HC; Zhu T; Grandison PM; Liu DX; Lobie PE
Neoplasia; 2010 Dec; 12(12):1041-53. PubMed ID: 21170268
[TBL] [Abstract][Full Text] [Related]
3. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.
Banerjee A; Wu ZS; Qian P; Kang J; Pandey V; Liu DX; Zhu T; Lobie PE
Breast Cancer Res; 2011; 13(6):R112. PubMed ID: 22060274
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
5. Artemin is oncogenic for human mammary carcinoma cells.
Kang J; Perry JK; Pandey V; Fielder GC; Mei B; Qian PX; Wu ZS; Zhu T; Liu DX; Lobie PE
Oncogene; 2009 May; 28(19):2034-45. PubMed ID: 19363524
[TBL] [Abstract][Full Text] [Related]
6. Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.
Banerjee A; Qian P; Wu ZS; Ren X; Steiner M; Bougen NM; Liu S; Liu DX; Zhu T; Lobie PE
J Biol Chem; 2012 Dec; 287(51):42502-15. PubMed ID: 23095743
[TBL] [Abstract][Full Text] [Related]
7. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
8. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
[TBL] [Abstract][Full Text] [Related]
9. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
10. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
12. Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.
Ding K; Banerjee A; Tan S; Zhao J; Zhuang Q; Li R; Qian P; Liu S; Wu ZS; Lobie PE; Zhu T
J Biol Chem; 2014 Jun; 289(23):16057-71. PubMed ID: 24737320
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
Glaeser M; Niederacher D; Djahansouzi S; Hanstein B; Dittrich R; Beckmann MW; Fasching PA; Ackermann S
Anticancer Res; 2006; 26(1B):735-44. PubMed ID: 16739346
[TBL] [Abstract][Full Text] [Related]
14. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
15. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.
Banerjee A; Wu ZS; Qian PX; Kang J; Liu DX; Zhu T; Lobie PE
PLoS One; 2012; 7(11):e50098. PubMed ID: 23185544
[TBL] [Abstract][Full Text] [Related]
16. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
Joffroy CM; Buck MB; Stope MB; Popp SL; Pfizenmaier K; Knabbe C
Cancer Res; 2010 Feb; 70(4):1314-22. PubMed ID: 20145137
[TBL] [Abstract][Full Text] [Related]
19. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
20. Clusterin: a potential target for improving response to antiestrogens.
Toffanin S; Daidone MG; Miodini P; De Cecco L; Gandellini P; Cappelletti V
Int J Oncol; 2008 Oct; 33(4):791-8. PubMed ID: 18813793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
